Shots:

• Novavax to receive royalties on the sales of vaccines and will provide its Matrix-M vaccine adjuvant to SII. Additionally- the company gets right to commercialize SII-manufactured vaccine in high-income countries- primarily in the travelers and military vaccine markets
• SII gets access to utilize Novavax’s Matrix-M vaccine adjuvant with its malaria vaccine candidate (R21 malaria vaccine)- licensed from the Jenner Institute at Oxford University in 2017
• R21 malaria vaccine along with Matrix-M is currently being evaluated in P-IIb study to target Plasmodium falciparum-induced malaria with its expected results to be reported in Q2’20

Click here ­to­ read full press release/ article | Ref: Novavax  | Image: Fierce Pharma